Tekla Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, … Read more
Market Cap & Net Worth: Tekla Life Sciences Investors (HQL)
Tekla Life Sciences Investors (NYSE:HQL) has a market capitalization of $491.93 Million ($491.93 Million) as of March 19, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #40056 globally and #13019 in its home market, demonstrating a 4.73% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tekla Life Sciences Investors's stock price $16.62 by its total outstanding shares 29598692 (29.60 Million).
Tekla Life Sciences Investors Market Cap History: 2015 to 2026
Tekla Life Sciences Investors's market capitalization history from 2015 to 2026. Data shows growth from $299.11 Million to $491.93 Million (4.78% CAGR).
Tekla Life Sciences Investors Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tekla Life Sciences Investors's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.75x
Tekla Life Sciences Investors's market cap is 5.75 times its annual revenue
2.92x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
5.80x
Tekla Life Sciences Investors's market cap is 5.80 times its annual earnings
4.96x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $240.91 Million | $6.29 Million | -$11.91 Million | 38.29x | N/A |
| 2017 | $302.37 Million | $69.81 Million | $68.56 Million | 4.33x | 4.41x |
| 2018 | $253.44 Million | $1.99 Million | $28.66 Million | 127.62x | 8.84x |
| 2019 | $318.15 Million | $-69.34 Million | -$70.48 Million | -4.59x | N/A |
| 2020 | $393.62 Million | $124.08 Million | $123.05 Million | 3.17x | 3.20x |
| 2021 | $415.36 Million | $65.69 Million | $64.53 Million | 6.32x | 6.44x |
| 2022 | $335.57 Million | $-103.25 Million | -$104.60 Million | -3.25x | N/A |
| 2023 | $349.76 Million | $23.52 Million | $22.35 Million | 14.87x | 15.65x |
| 2024 | $388.33 Million | $86.69 Million | $85.30 Million | 4.48x | 4.55x |
| 2025 | $496.67 Million | $86.39 Million | $85.59 Million | 5.75x | 5.80x |
Competitor Companies of HQL by Market Capitalization
Companies near Tekla Life Sciences Investors in the global market cap rankings as of March 19, 2026.
Key companies related to Tekla Life Sciences Investors by market ranking:
- BlackRock Inc (NYSE:BLK): Ranked #131 globally with a market cap of $139.78 Billion USD.
- Blackstone Group Inc (NYSE:BX): Ranked #245 globally with a market cap of $83.28 Billion USD.
- INVESTOR B (FRIA) O.N. (F:IVSD): Ranked #246 globally with a market cap of $83.12 Billion USD ( €80.97 Billion EUR).
- Brookfield Corp (NYSE:BN): Ranked #276 globally with a market cap of $76.43 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #131 | BlackRock Inc | NYSE:BLK | $139.78 Billion | $971.01 |
| #245 | Blackstone Group Inc | NYSE:BX | $83.28 Billion | $112.00 |
| #246 | INVESTOR B (FRIA) O.N. | F:IVSD | $83.12 Billion | €33.16 |
| #276 | Brookfield Corp | NYSE:BN | $76.43 Billion | $39.71 |
Tekla Life Sciences Investors Historical Marketcap From 2015 to 2026
Between 2015 and today, Tekla Life Sciences Investors's market cap moved from $299.11 Million to $ 491.93 Million, with a yearly change of 4.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $491.93 Million | -0.95% |
| 2025 | $496.67 Million | +27.90% |
| 2024 | $388.33 Million | +11.03% |
| 2023 | $349.76 Million | +4.23% |
| 2022 | $335.57 Million | -19.21% |
| 2021 | $415.36 Million | +5.52% |
| 2020 | $393.62 Million | +23.72% |
| 2019 | $318.15 Million | +25.53% |
| 2018 | $253.44 Million | -16.18% |
| 2017 | $302.37 Million | +25.51% |
| 2016 | $240.91 Million | -19.46% |
| 2015 | $299.11 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Tekla Life Sciences Investors was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $491.93 Million USD |
| MoneyControl | $491.93 Million USD |
| MarketWatch | $491.93 Million USD |
| marketcap.company | $491.93 Million USD |
| Reuters | $491.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.